Education
About Us
Working with TipRanks
Follow Us
Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
$1.66
-$0.36(-15.79%)
At close: 4:00 PM EST
$1.66
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.64
Previous CloseN/A
Volume307.14K
Average Volume (3M)4.53M
Market Cap
$247.35M
Enterprise Value-$1.81M
Total Cash (Recent Filing)$5.23M
Total Debt (Recent Filing)$211.00K
Price to Earnings (P/E)―
Beta-0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding149,003,200
10 Day Avg. Volume4,196,076
30 Day Avg. Volume4,525,639
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.81K
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$13.00Price Target Upside683.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital And Investor SupportA recent financing round that drew prominent healthcare-focused institutional investors strengthens funding for pivotal studies and supports an analyst-driven lift in valuation expectations.
Early Clinical Efficacy And SafetyEarly-phase data demonstrated rapid clinical responses and favorable tolerability, which could materially lower the risk of failure when advancing into larger ulcerative colitis trials.
Mechanism Of ActionPALI-2108 is an oral PDE4 prodrug engineered for gut-targeted activation, potentially increasing the therapeutic window by concentrating anti-inflammatory, anti-fibrotic, and pro-kinetic effects at the disease site.
Bears Say
Clinical Development RiskPositive signals from early studies might not replicate in larger trials or in the specific fibrostenotic Crohn’s disease population targeted for approval, risking program setbacks.
Financing And Commercial Execution RiskOngoing funding requirements and the need to build commercial capabilities for a niche indication could pressure valuation if additional capital or partnering is not secured.
Regulatory RiskRegulatory uncertainty around approval pathways for a localized PDE4 prodrug may complicate interactions with authorities and extend timelines to market authorization.
Palisade Bio News
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.53 and its highest was $2.64 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $247.35M.
When is Palisade Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Palisade Bio’s earnings last quarter?
Currently, no data Available
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 149,003,200 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (683.13% Upside)
$13.00 (683.13% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $9.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 32.9%
Last 30 Days ▲ 32.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.46%
12-Months-Change
Fundamentals
Return on Equity
-228.64%
Trailing 12-Months
Asset Growth
-25.31%
Trailing 12-Months
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$13.00
▲(683.13% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
0.01% Insiders
0.02% Mutual Funds
0.03% Other Institutional Investors
99.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---